Natixis Acquires 4,876 Shares of Biogen Inc. $BIIB

Natixis lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 16.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 34,781 shares of the biotechnology company’s stock after buying an additional 4,876 shares during the period. Natixis’ holdings in Biogen were worth $4,368,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of BIIB. Elevation Point Wealth Partners LLC bought a new stake in Biogen during the second quarter worth about $25,000. Zions Bancorporation National Association UT acquired a new position in shares of Biogen during the 1st quarter worth approximately $29,000. Rothschild Investment LLC raised its stake in shares of Biogen by 64.7% during the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 88 shares in the last quarter. Concord Wealth Partners boosted its holdings in shares of Biogen by 100.0% in the 2nd quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 114 shares during the last quarter. Finally, NewSquare Capital LLC grew its stake in shares of Biogen by 134.6% in the second quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 140 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Trading Up 1.0%

Shares of BIIB stock opened at $177.55 on Thursday. Biogen Inc. has a 12-month low of $110.04 and a 12-month high of $185.17. The company has a market capitalization of $26.05 billion, a PE ratio of 16.19, a price-to-earnings-growth ratio of 1.48 and a beta of 0.13. The firm has a 50 day moving average price of $160.81 and a two-hundred day moving average price of $143.18. The company has a quick ratio of 2.04, a current ratio of 2.72 and a debt-to-equity ratio of 0.35.

Biogen (NASDAQ:BIIB) last posted its earnings results on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, beating the consensus estimate of $3.89 by $0.92. The company had revenue of $2.53 billion for the quarter, compared to the consensus estimate of $2.34 billion. Biogen had a return on equity of 14.13% and a net margin of 15.98%.The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.08 earnings per share. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. As a group, analysts predict that Biogen Inc. will post 15.83 earnings per share for the current year.

Wall Street Analyst Weigh In

BIIB has been the topic of several analyst reports. Stifel Nicolaus raised shares of Biogen from a “hold” rating to a “buy” rating and upped their price target for the stock from $144.00 to $202.00 in a research report on Thursday, November 6th. Royal Bank Of Canada lowered their price objective on shares of Biogen from $217.00 to $210.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Robert W. Baird cut their target price on shares of Biogen from $255.00 to $250.00 in a research note on Friday, October 31st. Sanford C. Bernstein lifted their price target on Biogen from $155.00 to $157.00 and gave the stock a “market perform” rating in a report on Monday, November 3rd. Finally, Guggenheim boosted their price target on Biogen from $165.00 to $185.00 in a research report on Friday, October 31st. Ten analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $182.20.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.